scholarly journals New Biologic Drugs for Ulcerative Colitis

10.5772/26215 ◽  
2011 ◽  
Author(s):  
Francesca Zorzi ◽  
Emma Calabrese ◽  
Francesco Pallone
Keyword(s):  
Ulcerative Colitis ◽  
Biologic Drugs

Biologic Drugs in Crohn';s Disease and Ulcerative Colitis: Safety Profile

2016 ◽  
Vol 11 (1) ◽  
pp. 55-61 ◽  
Author(s):  
Antonio Di Sario ◽  
Emanuele Bendia ◽  
Laura Schiadà ◽  
Paola Sassaroli ◽  
Antonio Benedetti
Keyword(s):  
Ulcerative Colitis ◽  
Safety Profile ◽  
Biologic Drugs

scholarly journals Evaluation of efficacy and comparative frequency of adverse events in patients with ulcerative colitis receiving the original infliximab and its biosimilar. One year of observation

2019 ◽  
Vol 91 (8) ◽  
pp. 41-46
Author(s):  
O V Knyazev ◽  
T V Shkurko ◽  
A V Kagramanova ◽  
A A Lishchinskaya ◽  
M Yu Zvyaglova ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Adverse Events ◽  
Real Life ◽  
Fecal Calprotectin ◽  
Biologic Drugs ◽  
Real Life Data ◽  
Bowel Diseases ◽  
Significant Clinical Improvement ◽  
One Year

Real - life data on the effectiveness and safety of biosimilar and biologic drugs licensed for treatment of inflammatory bowel diseases (IBD) is lacking. Aim. To investigate efficacy of original Infliximab (IFX) and its biosimilar in treating patients with ulcerative colitis (UC) and determine the frequency of adverse events during 1 year follow - up period. Materials and methods. Our cohort consisted of 98 ulcerative colitis patients, treated with original IFX and its biosimilar since December 2017 till December 2018 years. Original Infliximab was prescribed in 56 UC patients (57.1%) during 5 years and longer; 16 patients (16.3%) were switched to IFX biosimilar; 13 UC bio - naïve patients (13.3%) received original IFX, 29 (29.6%) patients - biosimilar IFX. In 14 patients (14.3%) original infliximab was rotated with biosimilar. We picked out 42 patients to assess efficacy of original IFX and biosimilar. Results and discussion. Twelve patients, received original IFX and 28 patients, treated with its biosimilar, showed significant clinical improvement by decreasing Mayo index from 9.7±0.4 and 10.2±0.2 points to 1.9±0.09 and 2.1±0.1 points, accordingly. Also we noticed positive change in laboratory markers - CRP decrease from 89.6±8.7 mg/l and 77.5±8.0 mg/l to 6.5±0.8 mg/l and 6.9±0.8 mg/l (p>0.05), albumin increase from 30.1±4.7 g/l and 29.6±3.6 g/l to 34.1±6.3 g/l and 32.8±5.9 g/l (p>0.05), increase of serum iron levels from 6.4±0.5 mcg/l and 7.1±0.65 mcg/l to 14.6±4.4 mcg/l and 15.9±5.1 mcg/l (p>0.05), hemoglobin increase from 104.7±9.8 g/l and 102.2±8.8 g/l till 124±11.3 g/l and 121±10.9 g/l (p>0.05), and fecal calprotectin decrease from 1680±134 mcg/g and 1720±126 mcg/g till 245.5±33.4 mcg/g and 230.5±29.8 mcg/g (p>0.05). During 1 year follow - up 12 UC patients, treated with original IFX and its biosimilar, developed adverse events. The majority of adverse events (n=8) were registered in patients, rotating administration of original IFX and its biosimilar. Conclusion. IFX biosimilar is effective as well as original IFX. Frequency of adverse events, occurred in patients, treated with original IFX, was comparable with adverse events frequency in patients, received biosimilar IFX. Frequency of adverse events was significantly higher in UC patients, rotating original IFX and its biosimilar.

scholarly journals P797 Costs distribution of conventional or biologic drugs in ulcerative colitis and Crohn’s disease: A single outpatient centre experience

2018 ◽  
Vol 12 (supplement_1) ◽  
pp. S514-S515
Author(s):  
N Labarile ◽  
A Contaldo ◽  
M Corrieri ◽  
G Losurdo ◽  
R Lovero ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Biologic Drugs

scholarly journals Ulcerative colitis in combination with ankylosing spondylitis: clinical case

2020 ◽  
Vol 183 (11) ◽  
pp. 147-150
Author(s):  
D. D. Tarasova ◽  
L. N. Shilova ◽  
M. V. Korolyova ◽  
E. G. Korenskaya ◽  
A. V. Feoktistova
Keyword(s):  
Ulcerative Colitis ◽  
Ankylosing Spondylitis ◽  
Inflammatory Bowel Diseases ◽  
Clinical Case ◽  
Modern Medicine ◽  
Genetically Engineered ◽  
Topical Problem ◽  
Biologic Drugs ◽  
Bowel Diseases ◽  
Inflammatory Bowel

The combination of inflammatory bowel diseases with lesions of the spine and joints is an topical problem for modern medicine. A case of combination of ulcerative colitis and sacroiliitis is presented. The patient is recommended the therapy of genetically engineered biologic drugs.

scholarly journals Ig Glycosylation in Ulcerative Colitis: It’s Time for New Biomarkers

2021 ◽  
Vol 12 ◽  
Author(s):  
Riccardo Capecchi ◽  
Paola Migliorini ◽  
Federico Zanzi ◽  
Simona Maltinti ◽  
Ilaria Puxeddu ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Clinical Remission ◽  
Solid Phase ◽  
Binding Capacity ◽  
Protein A ◽  
Mucosal Healing ◽  
Therapeutic Outcome ◽  
Serum Samples ◽  
Biologic Drugs ◽  
Number Of Patients

Background: Ulcerative colitis (UC) is a chronic relapsing disease, which needs a continue monitoring, especially during biological therapies. An increasing number of patients is treated with anti-Tumor Necrosis factor (TNF) drugs, and current research is focalized to identify biomarkers able to monitor the disease and to predict therapeutic outcome.Methods: We enrolled consecutive UC patients treated with anti-TNF, naïve to biologic drugs. Therapeutic outcome was evaluated after 54 weeks of treatment in terms of clinical remission (Partial Mayo Score -PMS- <2) and mucosal healing (Mayo Endoscopic Score <2). On serum samples collected at baseline and after 54 weeks of treatment, a Lectin-based ELISA assay was performed, and specific glycosylation patterns were evaluated by biotin-labelled lectins. We have also collected 21 healthy controls (NHS) samples, age and sex-matched.Results: Out of 44 UC patients enrolled, 22 achieved clinical remission and mucosal healing after 54 weeks. At baseline, when Protein A was used as coating, UC patients non-responders showed a reduced reactivity to Jacalin (JAC) in comparison with NHS (p = 0.04). After one year of treatment, a decrease in JAC binding was seen only in responders, in comparison with baseline (p = 0.04). When JAC binding was tested selecting IgG by means of Fab anti-IgG Fab, UC patients displayed an increased reactivity after anti-TNF therapy (p < 0,0001 vs controls). At baseline, PMS inversely correlates with JAC binding when Fab anti-IgG Fab was used in solid phase (r2 = 0,2211; p = 0,0033). Patients with higher PMS at baseline (PMS ≥5) presented lower binding capacity for JAC in comparison with NHS and with lower PMS patients (p = 0,0135 and p = 0,0089, respectively).Conclusion: Ig glycosylation was correlated with clinical and endoscopic activity in patients with UC. JAC protein A-selected Ig showed a possible role in predicting therapeutic effectiveness. If these data would be confirmed, Ig glycosylation could be used as biomarker in UC.

scholarly journals P456 Ig glycosylation in ulcerative colitis: it’s time for new biomarkers

2021 ◽  
Vol 15 (Supplement_1) ◽  
pp. S450-S451
Author(s):  
R Capecchi ◽  
P Migliorini ◽  
F Zanzi ◽  
S Maltinti ◽  
I Puxeddu ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Clinical Remission ◽  
Solid Phase ◽  
Binding Capacity ◽  
Protein A ◽  
Mucosal Healing ◽  
Therapeutic Outcome ◽  
Serum Samples ◽  
Biologic Drugs ◽  
Number Of Patients

Abstract Background Ulcerative colitis (UC) is a chronic relapsing disease, which needs a continue monitoring, especially during biological therapies. An increasing number of patients is treated with anti-Tumor Necrosis factor (TNF) drugs, and current research is focalized to identify biomarkers able to monitor the disease and to predict therapeutic outcome. Methods We enrolled consecutive UC patients treated with anti-TNF, naïve to biologic drugs. Therapeutic outcome was evaluated after 54 weeks of treatment in terms of clinical remission (Partial Mayo Score -PMS- <2) and mucosal healing (Mayo Endoscopic Score <2). On serum samples collected at baseline and after 54 weeks of treatment, a Lectin-based ELISA assay was performed, and specific glycosylation patterns were evaluated by biotin-labelled lectins. We have also collected 21 healthy controls (NHS) samples, age and sex-matched. Results Out of 44 UC patients enrolled, 22 achieved clinical remission and mucosal healing after 54 weeks. At baseline, when Protein A was used as coating, UC patients non-responders showed a reduced reactivity to Jacalin (JAC) in comparison with NHS (p=0,04). After one year of treatment, a decrease in JAC binding was seen only in responders, in comparison with baseline (p=0,04). When JAC binding was tested selecting IgG by means of Fab anti-IgG Fab, UC patients displayed an increased reactivity after anti-TNF therapy (p<0,0001 vs controls). At baseline, PMS inversely correlates with JAC binding when Fab anti-IgG Fab was used in solid phase (r2= 0,2211; p=0,0033). Patients with higher PMS at baseline (PMS ≥5) presented lower binding capacity for JAC in comparison with NHS and with lower PMS patients (p= 0,0135 and p=0,0089 , respectively). Conclusion Ig glycosylation was correlated with clinical and endoscopic activity in patients with UC. JAC protein A-selected Ig showed a possible role in predicting therapeutic effectiveness. If these data would be confirmed, Ig glycosylation could be used as biomarker in UC.

Sign in / Sign up

Export Citation Format

Share Document